Phase 2 Trial of BX004, Phage Therapy for Bacterial Infections, Advancing

Phase 2 Trial of BX004, Phage Therapy for Bacterial Infections, Advancing

291480

Phase 2 Trial of BX004, Phage Therapy for Bacterial Infections, Advancing

A Phase 2 clinical trial assessing the safety and efficacy of BX004 — BiomX’s phage therapy candidate for Pseudomonas aeruginosa infections in people with cystic fibrosis (CF) — remains on track to have results by the end of this year, the company announced. While this timeline had been announced in a prior update, BiomX added that BX004 is now its selected investigational treatment for CF. P. aeruginosa is the most common bacteria in lung infections and severe lung disease…

You must be logged in to read/download the full post.